Zentalis Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Zentalis Pharmaceuticals is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -4.47 Dollars per share in 2023, which was 20.43 lower than 2021. And about -0.2084 billion Dollars are reported as free cash flow in the financials of Zentalis Pharmaceuticals 2023. No dividends were paid to the shareholders of the Zentalis Pharmaceuticals stock NasdaqGM:ZNTL in the financial year 2023.

$0.00M

Revenue

$-4.48

Earnings Per Share

0.00%

Gross Margin %

$-,215.46M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-4.48

Gross Margin %

0.00

Free Cash Flow

-,215.46

Financials

Year	Year	TTM	2022	2021	2020
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-4.60	$-4.48	$-3.72	$-4.19
Div.	Dividends	N/A	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	0
Sha.	Shares	N/AM	59.42M	45.56M	41.04M
OCF	Operating Cash Flow	N/A	$-,163.75M	$-,154.09M	$0.00M
FCF	Free Cash Flow	N/A	$-,215.46M	$-,205.25M	$-,127.67M
FCFS	Free Cash Flow Per Share	$-3.30	$-3.15	$-3.75	$-3.12

Zentalis Pharmaceuticals financials at a glance

Financials

Discover